Medication adherence in migraine patients (data of an online survey)
https://doi.org/10.14412/2074-2711-2021-4-81-87
Abstract
Patient needs, drug intake patterns, and adherence to therapy are significant challenges in the management of migraine patients.
Objective: to identify drug treatment needs, drug use patterns and adherence factors in migraine patients.
Patients and methods. An online survey was conducted among Internet users through social networks (Instagram, Facebook, Vkontakte) from 01/22/2020 to 02/22/2020. The selection of respondents was based on an anamnesis of headaches and passing the ID Migraine screener. One thousand five hundred ninety-eight individuals (93.8% women and 6.2% men) aged 18—39years participated in the survey.
Results and discussion. Among 1598 participants, 1490 experienced any headache, 937 respondents noted migraine symptoms, and 542 (58.4%) had a migraine diagnosis. 899 (96%) of responders used medications to relieve headaches, and in 59% of them drugs were self-prescribed. 125 (13%) patients received prophylactic therapy for migraine, of which only 47 (37.6%) complied with the prescribed treatment. We found a significant (p=0.019) association between the degree of adherence to therapy and the number of days with migraine.
Conclusion. The study revealed a low referral rate in patients with headaches. In addition, more than half self-prescribed the drug for headache relief, and only a third of patients complied with the prescribed prophylactic treatment.
About the Authors
N. A. Kovalchuk
Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Nadezhda Aleksandrovna Kovalchuk.
11, Rossolimo St., Build. 1, Moscow 119021.
Competing Interests:
There are no conflicts of interest.
E. A. Kiryanova
Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021.
Competing Interests:
There are no conflicts of interest.
G. R. Tabeeva
Department of Nervous System Diseases and Neurosurgery, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
11, Rossolimo St., Build. 1, Moscow 119021.
Competing Interests:
There are no conflicts of interest.
References
1. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-80. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.
2. Lipton RB, Serrano D, Holland S, et al. Barriers to the diagnosis and treatment of migraine: Effects of sex, income, and headache features. Headache. 2013 Jan;53(1):81-92. doi: 10.1111/j.1526-4610.2012.02265.x. Epub 2012 Oct 18.
3. Peh KQE, Kwan YH, Goh H, et al. An Adaptable Framework for Factors Contributing to Medication Adherence: Results from a Systematic Review of 102 Conceptual Frameworks. J Gen Intern Med. 2021 Mar 3. doi: 10.1007/s11606-021-06648-1. Epub ahead of print.
4. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013 Apr;53(4):644-55. doi: 10.1111/head.12055. Epub 2013 Mar 4.
5. Dodick DW, Loder EW, Manack Adams A, et al. Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2016 May;56(5):821-34. doi: 10.1111/head.12774. Epub 2016 May 3.
6. Krause SJ, Tepper SJ, Hu HX, Bigal ME. Adherence to Acute Migraine Medication: What Does It Mean, Why Does It Matter? Headache. 2010 Jan;50(1):117-29. doi: 10.1111/j.1526-4610.2009.01535.x. Epub 2009 Oct 8.
7. Lipton RB, Dodick D, Sadovsky R, et al; ID Migraine validation study. A self-administered screener for migraine in primary care: The ID Migraine validation study. Neurology. 2003 Aug 12;61(3):375-82. doi: 10.1212/01.wnl.0000078940.53438.83
8. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a selfreported measure of medication adherence. Med Care. 1986 Jan;24(1):67-74. doi: 10.1097/00005650-198601000-00007
9. Tabeyeva GR. Treatment of a migraine attack: ways to optimize therapeutic approaches. Nervnyye bolezni. 2015;(3):2-8 (In Russ.).
10. Filatova EG, Osipova VV, Tabeeva GR, et al. Diagnosis and treatment of migraine: Russian experts' recommendations. Nevrologiya, neirop-sikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):4-14. doi: 10.14412/2074-2711-2020-4-4-14 (In Russ.).
11. World Health Organisation. Adherence to long-term therapies, evidence for action. Geneva; 2003 Available from: http://www.who.int2
12. Fernandez-Lazaro CI, Garcia-Gonzalez JM, Adams DP, et al. Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study. BMC Fam Pract. 2019 Sep 14;20(1):132. doi: 10.1186/s12875-019-1019-3
13. Rossiyane boryutsya s nedomoganiyami: bezret-septurnyy preparat ili narodnaya meditsina vmesto vizita k vrachu. Issledovaniye Nielsen [Russians are struggling with ailments: an over-the-counter drug or traditional medicine instead of a visit to the doctor. Nielsen Research]. Available from: www.acnielsen.ru (In Russ.).
14. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006 Jul 1;333(7557):15. doi: 10.1136/bmj.38875.675486.55. Epub 2006 Jun 21.
15. Lipton RB, Buse DC, Serrano D, et al. Examination of unmet treatment needs among persons with episodic migraine: Results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2013 Sep;53(8):1300-11. doi: 10.1111/head.12154. Epub 2013 Jul 23.
16. Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study. Headache. Nov-Dec 2012;52(10):1456-70. doi: 10.1111/j.1526-4610.2012.02223.x. Epub 2012 Jul 25.
17. Ayzenberg I, Katsarava Z, Sborowski A, et al. Headache-attributed burden and its impact on productivity and quality of life in Russia: structured healthcare for headache is urgently needed. Eur J Neurol. 2014 May;21(5):758-65. doi: 10.1111/ene.12380. Epub 2014 Feb 13.
18. Ayzenberg I, Katsarava Z, Mathalikov R, et al. The burden of headache in Russia: validation of the diagnostic questionnaire in a population-based sample. Eur J Neurol. 2011 Mar;18(3):454-9. doi: 10.1111/j.1468-1331.2010.03177.x. Epub 2010 Aug 16.
19. Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012 Apr;32(5):373-81. doi: 10.1177/0333102412438977. Epub 2012 Mar 6.
Review
For citations:
Kovalchuk NA, Kiryanova EA, Tabeeva GR. Medication adherence in migraine patients (data of an online survey). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(4):81-87. (In Russ.) https://doi.org/10.14412/2074-2711-2021-4-81-87
Views:
648
Email this article 